Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort
Objective To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid.Design Target trial emulation based on ComPaRe e-cohort.Data source ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-10-01
|
| Series: | BMJ Medicine |
| Online Access: | https://bmjmedicine.bmj.com/content/2/1/e000229.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850138447867543552 |
|---|---|
| author | Philippe Ravaud Viet-Thi Tran Elodie Perrodeau Julia Saldanha Isabelle Pane |
| author_facet | Philippe Ravaud Viet-Thi Tran Elodie Perrodeau Julia Saldanha Isabelle Pane |
| author_sort | Philippe Ravaud |
| collection | DOAJ |
| description | Objective To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid.Design Target trial emulation based on ComPaRe e-cohort.Data source ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of patients with long covid, in France.Methods Adult patients (aged ≥18 years) enrolled in the ComPaRe cohort before 1 May 2021 were included in the study if they reported a confirmed or suspected SARS-CoV-2 infection, symptoms persistent for >3 weeks after onset, and at least one symptom attributable to long covid at baseline. Patients who received a first covid-19 vaccine injection were matched with an unvaccinated control group in a 1:1 ratio according to their propensity scores. Number of long covid symptoms, rate of complete remission of long covid, and proportion of patients reporting an unacceptable symptom state at 120 days were recorded.Results 910 patients were included in the analyses (455 in the vaccinated group and 455 in the control group). By 120 days, vaccination had reduced the number of long covid symptoms (mean 13.0 (standard deviation 9.4) in the vaccinated group v 14.8 (9.8) in the control group; mean difference −1.8, 95% confidence interval −3.0 to −0.5) and doubled the rate of patients in remission (16.6% v 7.5%, hazard ratio 1.93, 95% confidence interval 1.18 to 3.14). Vaccination reduced the effect of long covid on patients' lives (mean score on the impact tool 24.3 (standard deviation 16.7) v 27.6 (16.7); mean difference −3.3, 95% confidence interval −5.7 to −1.0) and the proportion of patients with an unacceptable symptom state (38.9% v 46.4%, risk difference −7.4%, 95% confidence interval −14.5% to −0.3%). In the vaccinated group, two (0.4%) patients reported serious adverse events requiring admission to hospital.Conclusion In this study, covid-19 vaccination reduced the severity of symptoms and the effect of long covid on patients' social, professional, and family lives at 120 days in those with persistent symptoms of infection. |
| format | Article |
| id | doaj-art-a6ed18ebc6d64c8d975d02c7dcdb5df7 |
| institution | OA Journals |
| issn | 2754-0413 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Medicine |
| spelling | doaj-art-a6ed18ebc6d64c8d975d02c7dcdb5df72025-08-20T02:30:35ZengBMJ Publishing GroupBMJ Medicine2754-04132023-10-012110.1136/bmjmed-2022-000229Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohortPhilippe Ravaud0Viet-Thi Tran1Elodie Perrodeau2Julia Saldanha3Isabelle Pane4Université Paris Cité, Inserm, INRAE, Centre de Recherche Epidémiologie et Statistiques, Université Paris Cité, Paris, FranceUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris, France33 Center of Research in Epidemiology and Statistics Sorbonne Paris Cité, Paris, FranceUniversité Paris Cité, Paris, FranceCentre d’Epidémiologie Clinique, AP-HP, Hôpital Hôtel Dieu, F-75004 Paris, FranceObjective To evaluate the effect of covid-19 vaccination on the severity of symptoms in patients with long covid.Design Target trial emulation based on ComPaRe e-cohort.Data source ComPaRe long covid cohort, a nationwide e-cohort (ie, a cohort where recruitment and follow-up are performed online) of patients with long covid, in France.Methods Adult patients (aged ≥18 years) enrolled in the ComPaRe cohort before 1 May 2021 were included in the study if they reported a confirmed or suspected SARS-CoV-2 infection, symptoms persistent for >3 weeks after onset, and at least one symptom attributable to long covid at baseline. Patients who received a first covid-19 vaccine injection were matched with an unvaccinated control group in a 1:1 ratio according to their propensity scores. Number of long covid symptoms, rate of complete remission of long covid, and proportion of patients reporting an unacceptable symptom state at 120 days were recorded.Results 910 patients were included in the analyses (455 in the vaccinated group and 455 in the control group). By 120 days, vaccination had reduced the number of long covid symptoms (mean 13.0 (standard deviation 9.4) in the vaccinated group v 14.8 (9.8) in the control group; mean difference −1.8, 95% confidence interval −3.0 to −0.5) and doubled the rate of patients in remission (16.6% v 7.5%, hazard ratio 1.93, 95% confidence interval 1.18 to 3.14). Vaccination reduced the effect of long covid on patients' lives (mean score on the impact tool 24.3 (standard deviation 16.7) v 27.6 (16.7); mean difference −3.3, 95% confidence interval −5.7 to −1.0) and the proportion of patients with an unacceptable symptom state (38.9% v 46.4%, risk difference −7.4%, 95% confidence interval −14.5% to −0.3%). In the vaccinated group, two (0.4%) patients reported serious adverse events requiring admission to hospital.Conclusion In this study, covid-19 vaccination reduced the severity of symptoms and the effect of long covid on patients' social, professional, and family lives at 120 days in those with persistent symptoms of infection.https://bmjmedicine.bmj.com/content/2/1/e000229.full |
| spellingShingle | Philippe Ravaud Viet-Thi Tran Elodie Perrodeau Julia Saldanha Isabelle Pane Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort BMJ Medicine |
| title | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort |
| title_full | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort |
| title_fullStr | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort |
| title_full_unstemmed | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort |
| title_short | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort |
| title_sort | efficacy of first dose of covid 19 vaccine versus no vaccination on symptoms of patients with long covid target trial emulation based on compare e cohort |
| url | https://bmjmedicine.bmj.com/content/2/1/e000229.full |
| work_keys_str_mv | AT philipperavaud efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort AT vietthitran efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort AT elodieperrodeau efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort AT juliasaldanha efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort AT isabellepane efficacyoffirstdoseofcovid19vaccineversusnovaccinationonsymptomsofpatientswithlongcovidtargettrialemulationbasedoncompareecohort |